Abstract

BackgroundCHIP is an E3 ubiquitin ligase that plays contrast roles in diverse human malignancies, depending on its targets. To date, the mechanisms underlying the function of CHIP in gastric cancer remains unclear. Here, we aim to further clarify the effects of CHIP on the development and progression of gastric cancer and explore its potential target.MethodsStably transfected CHIP-shRNA and TRAF2-shRNA AGS gastric cancer cell lines were established using Lipofectamine 2000. Cell growth was measured by an xCelligence real-time monitoring system and colony formation assay. Cell proliferation was detected using CCK-8, Ki-67, or CFSE assays. Apoptosis was detected by TUNEL assay or Annexin V/PI-staining followed by flow cytometric analysis. Cell cycle distribution was detected by PI-staining followed by flow cytometric analysis. Cell migration and invasion abilities were measured by a real-time xCelligence system, Transwell insert, and scratch assays. The expression of cell cycle-related proteins, apoptosis-related proteins, AKT, ERK, NF-κB signaling subunits, MMP2, MMP9, and Integrin β-1 were detected by Western blotting analysis. NF-κB DNA-binding capability was quantified using an ELISA-based NF-κB activity assay. Gastric cancer tissue microarray was analyzed to investigate the expression of both CHIP and TRAF2, and their clinical significance.ResultsThe CHIP-silencing in the AGS cells was oncogenic evidenced by the appearance of capable of anchorage-independent growth. The CHIP-silencing significantly enhanced the AGS cell proliferation capability likely due to the induced phosphorylation of ERK. The CHIP-silencing significantly inhibited apoptosis due to increased expression of Bcl-2. The CHIP-silencing promoted the AGS cell migration and invasion abilities, likely by regulating the expression of Integrin β-1. TRAF2 expression was markedly decreased in the CHIP-overexpressing cells at protein level, but not at mRNA level. The TRAF2-silencing markedly inhibited the proliferation ability of the AGS cells, the defected cell proliferation and enhanced apoptosis were involved in. The TRAF2-silencing also attenuated the cell migration and invasion capacities of the AGS cells. Furthermore, the expression of CHIP was downregulated while the expression of TRAF2 was upregulated in gastric cancer tissues. TRAF2 expression is independent prognostic factors of gastric cancer. The expression of CHIP and TRAF2 was negatively correlated in the gastric cancer tissue. Lower CHIP or higher TRAF2 was significantly linked to shorter overall survival in gastric cancer patients.ConclusionsTRAF2 influenced diverse aspects of cellular behavior of gastric cancer cells, including cell growth, migration, and invasion, which was in contrast to the functions of CHIP. TRAF2 could be considered as an independent prognostic factor in gastric cancer patients. It is possible that TRAF2 was a substrate of CHIP and CHIP regulated the TRAF2/NF-κB axis, which modulated diverse cellular behaviors in the AGS gastric cancer cells.

Highlights

  • Carboxyl terminus of Hsc70-interacting protein (CHIP) is an E3 ubiquitin ligase that plays contrast roles in diverse human malignancies, depending on its targets

  • It is possible that TNF receptor-associated factor 2 (TRAF2) was a substrate of CHIP and CHIP regulated the TRAF2/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) axis, which modulated diverse cellular behaviors in the AGS gastric cancer cells

  • CHIP affects AGS cell growth The CHIP expression at mRNA level was decreased about 2.93-fold (p < 0.001) in the siCHIP cells (AGS cells transfected with the CHIP-short hairpin RNA (shRNA) plasmid) compared to that in the sictrl cells (AGS cells transfected with the control-shRNA plasmid) detected by quantitative real-time PCR (qRT-PCR) (Additional file 1: Fig. S1a)

Read more

Summary

Introduction

CHIP is an E3 ubiquitin ligase that plays contrast roles in diverse human malignancies, depending on its targets. The mechanisms underlying the function of CHIP in gastric cancer remains unclear. We aim to further clarify the effects of CHIP on the development and progression of gastric cancer and explore its potential target. Gastric cancer (GC) is a biologically heterogeneous disease that evolves in the background of diverse genetic and epigenetic alterations. Due to the asymptomatic early phase of GC, most of the patients are diagnosed at the advanced stage. The surgical resection of localized GC with the removal of adjacent lymph nodes is the only curative strategy, and patients with pathological stage II or III requires postoperative adjuvant chemotherapy [2]. A better understanding of the molecular characteristic of metastatic GC is in need

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call